Endometrial Cancer
FDA grants fast track designation to leukemia, lymphoma and endometrial cancer therapies
The FDA announced several regulatory actions.
'Surprisingly low' percentage of patients with cancer undergo germline genetic testing
Identification of inherited genetic mutations that elevate cancer risk and may be susceptible to targeted therapies has transformed oncology care.
FDA expands Jemperli approval for endometrial cancer
The FDA approved dostarlimab in combination with chemotherapy for certain women with endometrial cancer.
Selinexor maintenance extends PFS in endometrial cancer subgroup with high unmet need
Selinexor maintenance after systemic therapy extended median PFS more than four times longer than placebo for women with advanced or recurrent TP53 wild-type endometrial cancer, according to phase 3 study results.
Similar QOL benefit for dual endometrial cancer, urinary incontinence surgery vs. cancer surgery alone
Among women with stress urinary incontinence and endometrial intraepithelial neoplasia or early-stage cancer, concomitant surgeries for both conditions did not improve quality of life compared with cancer surgery alone, researchers reported.
FDA news: License applications accepted for melanoma, endometrial cancer therapies
The FDA announced several regulatory actions the past few weeks.
Data confirm benefit of dostarlimab regimen for women with advanced endometrial cancer
CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.
Metabolically healthy and unhealthy obesity increase obesity-related cancer risk
Metabolically healthy and unhealthy obesity appeared associated with increased risk for various obesity-associated cancer types, according to study results presented at European Congress on Obesity.
Durvalumab regimens extend PFS in advanced endometrial cancer
The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.
Deep learning model predicts risk for distant recurrence of endometrial cancer
A deep learning model accurately identified women with endometrial cancer at low and high risk for distant recurrence, according to research presented at American Association for Cancer Research Annual Meeting.